Literature DB >> 1005741

Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation.

S Bunting, R Gryglewski, S Moncada, J R Vane.   

Abstract

Fresh arterial tissue generates an unstable substance (prostablandin X) which relaxes vascular smooth muscle and potently inhibits platelet aggregation. The release of prostaglandin (PG) X can be stimulated by incubation with arachidonic acid or prostaglandin endoperoxides PGG2 or PGH2. The basal release of PGX or the release stimulated with arachidonic acid can be inhibited by previous treatment with indomethacin or by washing the tissue with a solution containing indomethacin. The formation of PGX from prostaglandin endoperoxides PGG2 or PGH2 is not inhibited by indomethacin. 15-hydroperoxy arachidonic acid (15-HPAA) inhibits the basal release of PGX as well as the release stimulated by arachidonic acid or prostaglandin endoperoxides (PGG2 or PGH2). Fresh arterial tissue obtained from control or indomethacin treated rabbits, when incubated with platelet rich plasma (PRP) generates PGX. This generation is inhibited by treating the tissue with 15-HPAA. A biochemical interaction between platelets and vessel wall is postulated by which platelets feed the vessel wall with prostaglandin endoperoxides which are utilized to form PGX. Formation of PGX could be the underlying mechanism which actively prevents, under normal conditions, the accumulation of platelets on the vessel wall.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1005741     DOI: 10.1016/0090-6980(76)90125-8

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  135 in total

1.  Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation.

Authors:  W N Charman; S A Charman; D C Monkhouse; S E Frisbee; E A Lockhart; S Weisman; G A Fitzgerald
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

Review 2.  Thromboxane synthase inhibitors and receptor antagonists.

Authors:  J Vermylen; H Deckmyn
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

Review 3.  Long-term blood pressure control: is there a set-point in the brain?

Authors:  Yasuhiro Nishida; Megumi Tandai-Hiruma; Takehito Kemuriyama; Kohsuke Hagisawa
Journal:  J Physiol Sci       Date:  2012-05       Impact factor: 2.781

Review 4.  Ion channel networks in the control of cerebral blood flow.

Authors:  Thomas A Longden; David C Hill-Eubanks; Mark T Nelson
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-09       Impact factor: 6.200

5.  The importance of endogenous prostaglandins other than prostacyclin, for the modulation of contractility of some rabbit blood vessels.

Authors:  U Förstermann; G Hertting; B Neufang
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

6.  Prostanoid synthesis by aortic rings in human blood: selective increase of prostacyclin mediated by a serum factor.

Authors:  J M Ritter
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

7.  Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells.

Authors:  A I Schafer; D D Crawford; M A Gimbrone
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

Review 8.  Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

Authors:  O C Trifan; T Hla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

9.  Release of labile cyclo-oxygenase products of arachidonic acid from kidney by endotoxin.

Authors:  K Ozsan; V Içöz; R K Türker
Journal:  Experientia       Date:  1984-08-15

Review 10.  Drug interactions with thrombolytic agents. Current perspectives.

Authors:  A de Boer; J M van Griensven
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.